Trial reportAnnals of surgical oncology2025
Preoperative Radiation Boost Results in Low Rates of Re-excision and Reduced Locoregional Treatment Time in Breast Cancer Patients.
Trial report in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Feasibility of Accelerated, Hypofractionated Radiotherapy in Women With Breast Cancer: A Phase II Trial
A Single Center Phase II Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Breast Cancer Patients
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Preoperative Radiation Boost Reduces Re-Excision Rate and Locoregional Treatment Time in Early-Stage Breast Cancer Patients.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundWe conducted a prospective, phase II trial in which a radiation tumor bed boost was delivered preoperatively instead of the standard postoperative approach for breast cancer patients. We hypothesized that a preoperative boost would result in a lower rate of re-excision and a shorter duration of locoregional therapy compared with a postoperative boost.
methodsPatients in this trial (NCT04871516) received a boost of 13.32 Gy in 4 fractions, followed by lumpectomy and whole-breast radiotherapy of 36.63 Gy in 11 fractions. The re-excision rate in this trial was compared with the literature-reported rate and with a cohort of contemporary patients at our institution. The time from initial diagnostic biopsy to completion of radiotherapy was compared with the same contemporary cohort and with patients treated in a previous prospective trial at our institution (NCT00909909) with the same fractionation scheme.
resultsAmong 89 patients who were included, three (3.4%) required re-excision for inadequate surgical margins. This rate was lower than the literature-reported rate of 17.2% (p = 0.0005) and was also lower than the contemporary cohort (13.48%, p = 0.015). The median locoregional treatment time was 109 days (42-258) in this trial, which was shorter than the median treatment time in both the previous trial [122 days (62-311), p = 0.0002] and the contemporary cohort [126 days (74-278), p ≤ 0.0001].
conclusionsLower re-excision rates and shorter time from initial diagnosis to completion of radiotherapy, as observed in this phase II trial, may reduce treatment costs and risk of wound complications, improve treatment experience, and enable earlier initiation of systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.